Anti-Ebola virus GP protein monoclonal antibody, and applications thereof

An Ebola virus and monoclonal antibody technology, applied in the field of biological immunology, can solve the problems of no treatment method, no legal and effective vaccine for Ebola disease, etc., and achieve the effect of high specificity and sensitivity
CN107541522AInactive Publication Date: 2018-01-05HUAZHONG AGRI UNIV
5 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
HUAZHONG AGRI UNIV
Publication Date
2018-01-05
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the technical field of biological immunology, and more specifically relates to an anti-Ebola virus GP protein monoclonal antibody, and applications thereof. The anti-Ebola virus GP protein monoclonal antibody is secreted by a hybridoma cell strain with a preservation number of CCTCC NO:C2016106. The invention also discloses a preparation method and applications of the anti-Ebola virus GP protein monoclonal antibody. The anti-Ebola virus GP protein monoclonal antibody is high in specificity and biological binding activity, is capable of reacting with sf9 cells infectedby recombinant baculovirus containing GP gene, and is not reacted with normal sf9 cells, so that the anti-Ebola virus GP protein monoclonal antibody can be used for preparation of kits used for detecting Ebola virus GP protein and immunoassay.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of biological immunology. It specifically relates to a monoclonal antibody against Ebola virus GP protein and its application. The Ebola virus monoclonal antibody is from mouse source. The monoclonal antibody has high specificity and sensitivity to the Ebola virus GP protein, and can be applied to the preparation of Ebola virus GP protein detection reagents. The present invention is for subsequent humanized transformation, develops a neutralizing antibody that neutralizes Ebola virus, and lays a material foundation for later development into an antibody for clinical treatment of Ebola virus disease. Background technique

[0002] Ebola virus disease (EVD) is a severe zoonotic disease with high mortality caused by Ebola virus (EBOV). The Ebola virus spreads from animal to animal, human to human, and animal to human, and has repeatedly caused major animal and human harm on the African continent. Among them,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More